TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02331433
Drug: APN1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: APN1125 orally at ascending doses
Study: NCT02331433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00377377
Drug: EP1572 (ghrelin agonist) oral and duodenal application
Normalized name: Somatropin and somatropin agonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03073980
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Acetaminophen for pain control during procedure
Study: NCT03073980
Drug: PO Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO Acetaminophen for pain control during procedure
Study: NCT03476941
Drug: Gentamicin Sulfate Inj 20mg/2ml vial for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
Study: NCT01194791
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
Study: NCT01724372
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01724372
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01616225
Drug: No Saizen Control (Standard IVF Protocol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
Study: NCT03476941
Drug: Clindamycin phosphate 6 mg/1ml for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
Study: NCT05069883
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group Oral steroid medication after Direct Vision Internal Urethrotomy
Study: NCT00000541
Drug: folic acid/Vitamin B6/Vitamin B12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05069883
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
Study: NCT00538395
Drug: Adriamycin, Taxol and Cytoxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT01561950
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
Study: NCT00754793
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive comparator; titrated as per protocol over 12 weeks
Study: NCT01507051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 0 to 3: 1 tablet placebo, identical to active tablet
Study: NCT03067753
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01043276
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00258210 220 µg using inhaler A
Study: NCT01043276
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
Study: NCT02908256
Drug: Geloplasma (PVI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
Study: NCT02908256
Drug: Geloplasma (delta PP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
Study: NCT00164112
Drug: Cooperstown 5+1 alone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00164112
Drug: Azithromycin plus Cooperstown 5+1
Normalized name: azithromycin 1 % Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00164112
Drug: Telithromycin plus Cooperstown 5+1
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00219284
Drug: Carbidopa/levodopa/entacapone
Normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
Study: NCT03028870
Drug: V120083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT03028870
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules
Study: NCT03028870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules to match V120083 and/or naproxen
Study: NCT03036085
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
Study: NCT03805945
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
Study: NCT02572141
Drug: Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
Study: NCT00112645
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416845
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02572141
Drug: Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
Study: NCT00767052
Drug: AZD1236
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg once daily or 75mg twice daily will be administered in multiple dose part.
Study: NCT00767052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching to the active in multiple dose part.
Study: NCT03437304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl dosing volume 200 μl, intranasal administration x 2
Study: NCT00002804
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00767052
Drug: AZD1236
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg single dose will be administered in relative bioavailability part.
Study: NCT00767052
Drug: AZD1236
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg oral suspension single dose will be administered in relative bioavailability part.
Study: NCT03059238
Drug: Celecoxib 200mg oral capsule
Normalized name: Celecoxib 200mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03652038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered via inhaler device
Study: NCT03015675
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20g/day, D1-3, every 2 weeks
Study: NCT03015675
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Study: NCT01350973
Drug: Eicosapentaenoic acid-ethyl (EPA-E)
Normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
Study: NCT02110368
Drug: AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03045770
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil was used as first line treatment with AGC.
Study: NCT03045770
Drug: calcium levofolinate
Normalized name: calcium levofolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium levofolinate was used as first line treatment with AGC.
Study: NCT02675491
Drug: DS-6051b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DS-6051b 400 mg or 800 mg daily
Study: NCT04465487
Drug: REGN6569
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT03053700
Drug: Bromonide 0.33% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
Study: NCT04381962
Drug: Azithromycin Capsule
Normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg OD PO 14 days
Study: NCT02482090
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study: NCT02408705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
Study: NCT00022867
Drug: Nondigestible oligosaccharide (NDO)
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01954394
Drug: Lipid-Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT01687998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT01337739
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (.9 normal saline sterile)
Study: NCT01182675
Drug: Transplant Conditioning with Mobilization Only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
Study: NCT03464305
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
Study: NCT03464305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
Study: NCT03326102
Drug: DHP107
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
Study: NCT03359291
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
Study: NCT00439634
Drug: AVE1625
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00439634
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00124059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/day placebo
Study: NCT01297179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00025818
Drug: Ophthalmic Emulsion
Normalized name: Retaine MGD Ophthalmic Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03670966
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03372694
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
Study: NCT03479996
Drug: Marcaine 0.5 % Injectable Solution
Normalized name: Marcaine 0.5 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra -operative injection into obturator membrane
Study: NCT02687542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01786200
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02079220
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Capecitabine~* Oxaliplatin~* Ziv-aflibercept
Study: NCT02079220
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine Oxaliplatin Ziv-aflibercept
Study: NCT00309543
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00309543
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03677830
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
Study: NCT01534312
Drug: Maximal oral 5ASA
Normalized name: Arthrospira Maxima
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4800 grams/day of Mesalazine (Asacol/Mezavant)
Study: NCT00705003
Drug: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
Study: NCT01898806
Drug: Intralesional Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
Study: NCT02575495
Drug: 7 days course of antibiotic treatment
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
Study: NCT03947320
Drug: Recombinant Human Coagulation FVIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Study: NCT03435861
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT01707134
Drug: human soluble insulin
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected subcutaneously (s.c, under the skin) as meal time insulin
Study: NCT01707134
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
Study: NCT02647944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03372694
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
Study: NCT03969849
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
Study: NCT03375463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00649324
Drug: Hydrochlorothiazide Tablets (50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg, single dose fasting
Study: NCT03185364
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebos treatment for 12 weeks
Study: NCT00509561
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01118273
Drug: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Study: NCT03303378
Drug: melatonin (Helsinn Chemical Co, Biasca, Switzerland)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
Study: NCT04290663
Drug: Systematic RAI-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
Study: NCT02367040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
Study: NCT04278391
Drug: DWJ1421
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered in fasting condition
Study: NCT04278391
Drug: DWC201903
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered in fasting condition
Study: NCT02465320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of bioadhesive gel administered by intravaginal insertion
Study: NCT02714062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po once daily
Study: NCT04665063
Drug: Cyclophosphamide,Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Cyclophosphamide,Fludarabine
Study: NCT02038621
Drug: Oxaliplatin and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
Study: NCT02953691
Drug: Galacto-Oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
Study: NCT02161783
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
Study: NCT03414593
Drug: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
Study: NCT03303378
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).